Ant Group Is Planning to Acquire Haodaifu Online, Shifting from Ali Health

TapTechNews August 15th news, according to the news cited by Jianwen Consulting under China Business News today, Ant Group is planning to acquire the Internet-based online consultation platform Haodaifu Online. Previously, it was Ant Group's sister company Ali Health that negotiated the acquisition with Haodaifu Online, but recently sources close to Ant Group revealed that the negotiator has now changed to Ant Group from Ali Health.

Ant Group Is Planning to Acquire Haodaifu Online, Shifting from Ali Health_0

After opening the Medical and Health channel on the homepage of Alipay and choosing the Online Consultation column, users can see the words Haodaifu, and the page content presented is consistent with the Expert Consultation interface of the Haodaifu Online App. The same doctors, the same order, and even the avatar photos, personal profiles, user ratings, and consultation prices are exactly the same. An insider of Alipay's medical and health business said that the two sides had reached relevant business cooperation at the end of June this year.

The report said that this sign means that the expert information and platform data of Haodaifu Online have been moved to the Alipay medical and health channel and become a new entrance to the Alipay medical ecosystem.

As of TapTechNews' dispatch, neither Ant Group nor Haodaifu Online has responded to this matter.

According to Tu Honggang, a medical industry researcher, compared to Ali Health, Alipay has a stronger platform attribute, and has more channels for traffic monetization. You can make some longer-term layouts and don't have to rely on short-term business to make money. In addition, The core resource of Haodaifu Online is tens of thousands of active famous doctors, which is a very good drainage tool for the platform.

Haodaifu Online was established in 2006. At its peak, the number of employees exceeded one thousand, and its valuation was nearly 10 billion yuan (about 1.43 billion US dollars). However, this enterprise lacks its own hematopoietic ability, and the team has been greatly reduced in recent years. Since then, the company has tried several commercial transformation attempts, but none has achieved the expected results.

Likes